These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 21382134)

  • 1. Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®).
    Bacon CL; Singleton E; Brady B; White B; Nolan B; Gilmore RM; Ryan C; Keohane C; Jenkins PV; O'Donnell JS
    Haemophilia; 2011 May; 17(3):407-11. PubMed ID: 21382134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low risk of inhibitor formation in haemophilia patients after a change in treatment from Chinese hamster ovary cell-produced to baby hamster kidney cell-produced recombinant factor VIII.
    Singleton E; Smith J; Kavanagh M; Nolan B; White B
    Thromb Haemost; 2007 Dec; 98(6):1188-92. PubMed ID: 18064312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective surveillance study of factor VIII inhibitor development in the Canadian haemophilia A population following the switch to a recombinant factor VIII product formulated with sucrose.
    Rubinger M; Lillicrap D; Rivard GE; Teitel J; Carcao M; Hensman C; Walker I;
    Haemophilia; 2008 Mar; 14(2):281-6. PubMed ID: 18194308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence between two serum-free recombinant factor VIII preparations (N8 and ADVATE®)--an open-label, sequential dosing pharmacokinetic study in patients with severe haemophilia A.
    Martinowitz U; Bjerre J; Brand B; Klamroth R; Misgav M; Morfini M; Santagostino E; Tiede A; Viuff D
    Haemophilia; 2011 Nov; 17(6):854-9. PubMed ID: 21443634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate.
    Gringeri A; Monzini M; Tagariello G; Scaraggi FA; Mannucci PM;
    Haemophilia; 2006 Mar; 12(2):128-32. PubMed ID: 16476086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant factor concentrates may increase inhibitor development: a single centre cohort study.
    Strauss T; Lubetsky A; Ravid B; Bashari D; Luboshitz J; Lalezari S; Misgav M; Martinowitz U; Kenet G
    Haemophilia; 2011 Jul; 17(4):625-9. PubMed ID: 21299743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment related factors and inhibitor development in children with severe haemophilia A.
    Maclean PS; Richards M; Williams M; Collins P; Liesner R; Keeling DM; Yee T; Will AM; Young D; Chalmers EA;
    Haemophilia; 2011 Mar; 17(2):282-7. PubMed ID: 21070501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin-free method] demonstrates efficacy, safety and low-risk for immunogenicity in routine clinical practice.
    Oldenburg J; Goudemand J; Valentino L; Richards M; Luu H; Kriukov A; Gajek H; Spotts G; Ewenstein B
    Haemophilia; 2010 Nov; 16(6):866-77. PubMed ID: 20579113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
    Peerlinck K; Hermans C
    Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
    J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and inhibitor development in previously treated patients with haemophilia A switched to a B domain-deleted recombinant factor VIII.
    Gringeri A; Tagliaferri A; Tagariello G; Morfini M; Santagostino E; Mannucci P;
    Br J Haematol; 2004 Aug; 126(3):398-404. PubMed ID: 15257713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
    Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of a plasma-derived monoclonal purified factor VIII concentrate during 10 years of follow-up.
    Mauser-Bunschoten EP; Posthouwer D; Fischer K; van den Berg HM
    Haemophilia; 2007 Nov; 13(6):697-700. PubMed ID: 17877729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A.
    Chalmers EA; Brown SA; Keeling D; Liesner R; Richards M; Stirling D; Thomas A; Vidler V; Williams MD; Young D;
    Haemophilia; 2007 Mar; 13(2):149-55. PubMed ID: 17286767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemophilia treatment. Factor VIII inhibitors with recombinant products: prospective clinical trials.
    Lusher JM
    Haematologica; 2000 Oct; 85(10 Suppl):2-5; discussion 5-6. PubMed ID: 11187864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A.
    Valentino LA; Recht M; Dipaola J; Shapiro AD; Pipe SW; Ewing N; Urgo J; Bullock T; Simmons M; Deguzman C
    Haemophilia; 2009 May; 15(3):718-26. PubMed ID: 19298383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.